Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Set To Grow From $8.92 Billion In 2026 To $11.04 Billion By 2030 At A CAGR Of 5.5%
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Expansion From $8.92 Billion In 2026 To $11.04 Billion In 2030
In recent years, the market for castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPCA) therapeutics has experienced substantial expansion. Projections indicate it will rise from $8.43 billion in 2025 to $8.92 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historic growth is driven by factors such as the high prevalence of prostate cancer, the development of resistance to hormone therapies, progress in oncology drug innovation, the provision of cancer care within hospital settings, and an increasing demographic of older men.
The market size for therapeutics targeting castration-resistant prostate cancer, also referred to as hormone-refractory prostate cancer, is projected to experience considerable expansion over the coming years. By 2030, this market is anticipated to reach $11.04 billion, reflecting a compound annual growth rate of 5.5%. This predicted growth during the forecast period is driven by factors such as the increasing reliance on biomarker-driven treatment strategies, the development of more advanced targeted therapies, a growing shift toward oral oncology medications, an expanding pipeline of oncology drugs, and a stronger emphasis on personalized cancer care. Key trends shaping the market in this period include the growing utilization of androgen receptor inhibitors, the expansion of PARP inhibitor therapies, the rising number of combination treatment protocols, a heightened focus on precision oncology, and a steady transition toward adopting oral oncology drugs.
Download A Free Sample Report For Comprehensive Market Insights:
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Opportunity Drivers: What Is Creating New Revenue Potential?
The increasing incidence of prostate cancer is expected to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is defined as a malignancy that develops in the prostate gland, a small male reproductive organ positioned beneath the bladder and in front of the rectum. This rise in prostate cancer cases is largely attributed to an aging population, given that the likelihood of developing this condition significantly escalates with advancing age. Therapeutics designed for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are utilized to manage the disease by focusing on its advanced phases, where it no longer reacts to standard hormone-based treatments. These therapies enhance patient outcomes by decelerating disease advancement and alleviating symptoms, which ultimately improves the quality of life. To illustrate, in October 2025, NHS Digital—a UK-based government body overseeing healthcare statistics—reported that England recorded 58,137 new prostate cancer cases in 2023, indicating a 6 percent rise from the previous year. Consequently, the growing prevalence of prostate cancer is fueling the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Innovation Trends Driving Future Development
Key players in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutic market are prioritizing the development of innovative products, including dual-action tablets, to improve treatment effectiveness and patient outcomes. These dual-action tablets are advanced formulations delivering two therapeutic agents in a single dose, designed to simultaneously target multiple pathways in the treatment of CRPC. A notable example occurred in August 2023, when Janssen Pharmaceuticals, a Belgium-based firm, secured U.S. Food and Drug Administration (FDA) approval for Akeega, a novel tablet intended for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This precision medicine integrates a PARP inhibitor (niraparib) and a CYP17 inhibitor (abiraterone acetate), specifically tailored for patients with BRCA mutations. When administered with prednisone, it markedly extends radiographic progression-free survival (rPFS) relative to standard hormonal therapy.
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Key Players And Strategic Industry Positioning
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Access The Complete Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
